⁹⁰Y/¹⁷⁷Lu-DOTATOC: From Preclinical Studies to Application in Humans

• Main Authors: Licia Uccelli (Author), Alessandra Boschi (Author), Corrado Cittanti (Author), Petra Martini (Author), Stefano Panareo (Author), Eugenia Tonini (Author), Alberto Nieri (Author), Luca Urso (Author), Matteo Caracciolo (Author), Luca Lodi (Author), Aldo Carnevale (Author), Melchiore Giganti (Author), Mirco Bartolomei (Author)
• Format: Book
• Published: MDPI AG, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in this type of therapy is a somatostatin-modified peptide fragment ([Tyr3] octreotide), equipped with a specific chelating system (DOTA) capable of creating a stable bond with β-emitting radionuclides, such as yttrium-90 and lutetium-177. In this review, covering twenty five years of literature, we describe the characteristics and performances of the two most used therapeutic radiopharmaceuticals for the NETs radio-treatment: [⁹⁰Y]Y-DOTATOC and [¹⁷⁷Lu]Lu-DOTATOC taking this opportunity to retrace the most significant results that have determined their success, promoting them from preclinical studies to application in humans.

Item Description

10.3390/pharmaceutics13091463
1999-4923